Year: 2024
Type: article
Abstract: In the past decade, oncology care has witnessed a transformative shift, significantly propelled by the growing field of precision medicine. This revolution has been catalyzed by a deeper understanding of cancer’s underlying biological drivers, unveiling new avenues to combat this multifaceted disease. For instance, the identification and targeting of the EGFR mutations have paved the way for personalized therapies in Non-Small Cell Lung Cancer (NSCLC). Traditionally, diagnostic labs played a more reserved, albeit crucial, role in the healthcare continuum, primarily focusing on providing diagnostic services. However, as further insights into cancer’s molecular intricacies emerge, biomarkers have become central to the endeavor of tailoring treatments to individual patients’ genetic and molecular profiles. This rising significance of biomarkers has recalibrated the role of and expectations from diagnostic labs, ushering them into a more proactive and collaborative role in oncology care. The shift from a one-size-fits-all approach to a more personalized, biomarker-driven therapeutic strategy in oncology has shown promise in enhancing treatment outcomes for patients and streamlining the drug development and approval processes for pharmaceutical industry. As biomarker knowledge expands, the traditional diagnostic lab has transitioned from a vendor of testing services to a strategic partner in drug development and clinical implementation.
DOI: 10.52916/jmrs244146
Author: Chen Yeh
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4402776904